At the Indiana University School of Medicine (IUSM)-Purdue TREAT-AD center, our strategic goal is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer’s Disease (AD) target hypotheses and etiologies with the goal of generating new classes of potential therapeutics. Specifically, the group will establish itself as a strategic and operational partner for the National Institute on Aging (NIA) Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) and Model Organism Development and Evaluation for Late Onset Alzheimer’s Disease (MODEL-AD) initiatives. By design, this will provide drug discovery capability to bridge the foundational work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics, and translational biomarkers (MODEL-AD). A key advantage and differentiated strength of the Center is the primary scientific coordination and administration through the Indiana University School of Medicine. Specifically, this concentrates a strong and long-standing commitment to neurodegenerative research through co-presence with the NIA-supported Indiana Alzheimer’s Disease Center, the MODEL-AD consortium, and the Longitudinal Early Onset Alzheimer’s Disease (LEAD) study.